Ji Young Yoo1, Jessica Swanner1, Yoshihiro Otani1, Mitra Nair1, Flora Park2, Yeshavanth Banasavadi-Siddegowda1,3, Joseph Liu4, Alena Cristina Jaime-Ramirez4, Bangxing Hong1, Feng Geng5, Deliang Guo5, Darlene Bystry6, Mitch Phelphs6, Haroon Quadri7, Tae Jin Lee1, Balveen Kaur1. 1. Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, Texas. 2. Rice University, Houston, Texas. 3. Surgical Neurology Branch, NINDS, NIH, Bethesda, Maryland. 4. Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, Ohio. 5. Department of Radiation Oncology, James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, Ohio. 6. Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, Ohio. 7. Northeast Ohio Medical University, Rootstown, Ohio.
Abstract
BACKGROUND: Hyperactivation of the RAS-RAF-MEK-ERK signaling pathway is exploited by glioma cells to promote their growth and evade apoptosis. MEK activation in tumor cells can increase replication of ICP34.5-deleted herpes simplex virus type 1 (HSV-1), but paradoxically its activation in tumor-associated macrophages promotes a pro-inflammatory signaling that can inhibit virus replication and propagation. Here we investigated the effect of blocking MEK signaling in conjunction with oncolytic HSV-1 (oHSV) for brain tumors. METHODS: Infected glioma cells co-cultured with microglia or macrophages treated with or without trametinib were used to test trametinib effect on macrophages/microglia. Enzyme-linked immunosorbent assay, western blotting, and flow cytometry were utilized to evaluate the effect of the combination therapy. Pharmacokinetic (PK) analysis of mouse plasma and brain tissue was used to evaluate trametinib delivery to the CNS. Intracranial human and mouse glioma-bearing immune deficient and immune competent mice were used to evaluate the antitumor efficacy. RESULT: Oncolytic HSV treatment rescued trametinib-mediated feedback reactivation of the mitogen-activated protein kinase signaling pathway in glioma. In vivo, PK analysis revealed enhanced blood-brain barrier penetration of trametinib after oHSV treatment. Treatment by trametinib, a MEK kinase inhibitor, led to a significant reduction in microglia- and macrophage-derived tumor necrosis factor alpha (TNFα) secretion in response to oHSV treatment and increased survival of glioma-bearing mice. Despite the reduced TNFα production observed in vivo, the combination treatment activated CD8+ T-cell mediated immunity and increased survival in a glioma-bearing immune-competent mouse model. CONCLUSION: This study provides a rationale for combining oHSV with trametinib for the treatment of brain tumors.
BACKGROUND: Hyperactivation of the RAS-RAF-MEK-ERK signaling pathway is exploited by glioma cells to promote their growth and evade apoptosis. MEK activation in tumor cells can increase replication of ICP34.5-deleted herpes simplex virus type 1 (HSV-1), but paradoxically its activation in tumor-associated macrophages promotes a pro-inflammatory signaling that can inhibit virus replication and propagation. Here we investigated the effect of blocking MEK signaling in conjunction with oncolytic HSV-1 (oHSV) for brain tumors. METHODS:Infected glioma cells co-cultured with microglia or macrophages treated with or without trametinib were used to test trametinib effect on macrophages/microglia. Enzyme-linked immunosorbent assay, western blotting, and flow cytometry were utilized to evaluate the effect of the combination therapy. Pharmacokinetic (PK) analysis of mouse plasma and brain tissue was used to evaluate trametinib delivery to the CNS. Intracranial human and mouseglioma-bearing immune deficient and immune competent mice were used to evaluate the antitumor efficacy. RESULT: Oncolytic HSV treatment rescued trametinib-mediated feedback reactivation of the mitogen-activated protein kinase signaling pathway in glioma. In vivo, PK analysis revealed enhanced blood-brain barrier penetration of trametinib after oHSV treatment. Treatment by trametinib, a MEK kinase inhibitor, led to a significant reduction in microglia- and macrophage-derived tumor necrosis factor alpha (TNFα) secretion in response to oHSV treatment and increased survival of glioma-bearing mice. Despite the reduced TNFα production observed in vivo, the combination treatment activated CD8+ T-cell mediated immunity and increased survival in a glioma-bearing immune-competent mouse model. CONCLUSION: This study provides a rationale for combining oHSV with trametinib for the treatment of brain tumors.
Authors: Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin Journal: Cell Date: 2013-10-10 Impact factor: 41.582
Authors: Roger Stupp; Sophie Taillibert; Andrew Kanner; William Read; David Steinberg; Benoit Lhermitte; Steven Toms; Ahmed Idbaih; Manmeet S. Ahluwalia; Karen Fink; Francesco Di Meco; Frank Lieberman; Jay-Jiguang Zhu; Giuseppe Stragliotto; David Tran; Steven Brem; Andreas Hottinger; Eilon D. Kirson; Gitit Lavy-Shahaf; Uri Weinberg; Chae-Yong Kim; Sun-Ha Paek; Garth Nicholas; Jordi Bruna; Hal Hirte; Michael Weller; Yoram Palti; Monika E. Hegi; Zvi Ram Journal: JAMA Date: 2017-12-19 Impact factor: 56.272
Authors: Bangxing Hong; Kamaldeen Muili; Chelsea Bolyard; Luke Russell; Tae Jin Lee; Yeshavanth Banasavadi-Siddegowda; Ji Young Yoo; Yuanqing Yan; Leomar Y Ballester; Kurt H Bockhorst; Balveen Kaur Journal: Mol Ther Oncolytics Date: 2018-12-06 Impact factor: 7.200
Authors: Yoshihiro Otani; Ji Young Yoo; Cole T Lewis; Samantha Chao; Jessica Swanner; Toshihiko Shimizu; Jin Muk Kang; Sara A Murphy; Kimberly Rivera-Caraballo; Bangxing Hong; Joseph C Glorioso; Hiroshi Nakashima; Sean E Lawler; Yeshavanth Banasavadi-Siddegowda; John D Heiss; Yuanqing Yan; Guangsheng Pei; Michael A Caligiuri; Zhongming Zhao; E Antonio Chiocca; Jianhua Yu; Balveen Kaur Journal: Clin Cancer Res Date: 2022-04-01 Impact factor: 13.801
Authors: Michael I Chastkofsky; Katarzyna C Pituch; Hiroaki Katagi; Markella Zannikou; Liliana Ilut; Ting Xiao; Yu Han; Adam M Sonabend; David T Curiel; Erin R Bonner; Javad Nazarian; Craig M Horbinski; C David James; Amanda M Saratsis; Rintaro Hashizume; Maciej S Lesniak; Irina V Balyasnikova Journal: Clin Cancer Res Date: 2020-12-03 Impact factor: 13.801
Authors: Antonio Dono; Anthony Patrizz; Ryan M McCormack; Nagireddy Putluri; Bhanu P Ganesh; Balveen Kaur; Louise D McCullough; Leomar Y Ballester; Yoshua Esquenazi Journal: CNS Oncol Date: 2020-06-30